NCT03886779View on ClinicalTrials.gov

Study Title: Clinical Outcomes of Prolensa (Bromfenac Ophthalmic Solution) 0.07% QD vs. Ilevro (Nepafenac Ophthalmic Suspension) 0.3% QD With Extra (Pulse) Dose on Day of Surgery for Treatment of Ocular Inflammation Associated With Cataract Surgery in a Randomized, Single Masked Clinical Trial

PHASE4CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

October 30, 2013

Primary Completion Date

February 15, 2017

Study Completion Date

March 31, 2019

Conditions
Treatment of Ocular Inflammation Associated With Cataract Surgery
Interventions
DRUG

Bromfenac

0.7 MG/ML \[Prolensa\]

DRUG

Nepafenac

3 MG/ML \[Ilevro\]

All Listed Sponsors
collaborator

Bausch & Lomb Incorporated

INDUSTRY

collaborator

Churchhill Communications

UNKNOWN

collaborator

Statistics & Data Corporation

INDUSTRY

lead

Silverstein Eye Centers

OTHER

NCT03886779 - Study Title: Clinical Outcomes of Prolensa (Bromfenac Ophthalmic Solution) 0.07% QD vs. Ilevro (Nepafenac Ophthalmic Suspension) 0.3% QD With Extra (Pulse) Dose on Day of Surgery for Treatment of Ocular Inflammation Associated With Cataract Surgery in a Randomized, Single Masked Clinical Trial | Biotech Hunter | Biotech Hunter